Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Accumulated Expenses (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Other Accumulated Expenses for 11 consecutive years, with $179000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses fell 64.27% year-over-year to $179000.0, compared with a TTM value of $179000.0 through Dec 2025, down 64.27%, and an annual FY2025 reading of $179000.0, down 64.27% over the prior year.
  • Other Accumulated Expenses was $179000.0 for Q4 2025 at Spyre Therapeutics, up from $170000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.1 million in Q2 2021 and bottomed at $170000.0 in Q3 2025.
  • Average Other Accumulated Expenses over 5 years is $472111.1, with a median of $378500.0 recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses surged 97.82% in 2022, then plummeted 67.68% in 2025.
  • Year by year, Other Accumulated Expenses stood at $783000.0 in 2021, then tumbled by 57.85% to $330000.0 in 2022, then soared by 47.88% to $488000.0 in 2023, then grew by 2.66% to $501000.0 in 2024, then plummeted by 64.27% to $179000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for SYRE at $179000.0 in Q4 2025, $170000.0 in Q3 2025, and $242000.0 in Q2 2025.